News Focus
News Focus
icon url

jbog

03/31/13 9:02 PM

#159097 RE: DewDiligence #159087

Being that Sanofi and Biogen drug had ample time to evaluate the marketplace prior to approval their respective pricing could be anything but a coincidence.

BG-12's trial results coupled with its modest pricing premium puts it in a sweet spot.